ロード中...
Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once‐daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmun...
保存先:
| 出版年: | Diabetes Obes Metab |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Publishing Ltd
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5067686/ https://ncbi.nlm.nih.gov/pubmed/26663320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12621 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|